261 related articles for article (PubMed ID: 31153036)
1. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use.
Santini V; Ossenkoppele GJ
Crit Rev Oncol Hematol; 2019 Aug; 140():1-7. PubMed ID: 31153036
[TBL] [Abstract][Full Text] [Related]
2. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
6. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
7. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Feld J; Tremblay D; Navada SC; Silverman LR
Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
[TBL] [Abstract][Full Text] [Related]
8. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
9. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
Hur EH; Jung SH; Goo BK; Moon J; Choi Y; Choi DR; Chung YJ; Lee JH
Oncotarget; 2017 Feb; 8(7):11748-11762. PubMed ID: 28052028
[TBL] [Abstract][Full Text] [Related]
11. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.
Xu R; Li M; Wu P; Deng C; Geng S; Huang X; Weng J; Du X
Hematology; 2021 Dec; 26(1):312-320. PubMed ID: 33706667
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Bohl SR; Bullinger L; Rücker FG
Expert Rev Hematol; 2018 May; 11(5):361-371. PubMed ID: 29543073
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee.
Neuendorff NR; Gagelmann N; Singhal S; Meckstroth S; Thibaud V; Zhao Y; Mir N; Shih YY; Amaro DMC; Roy M; Lombardo J; Gjærde LK; Loh KP
J Geriatr Oncol; 2023 Apr; 14(3):101406. PubMed ID: 36435726
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylating Agents as a Therapy for AML.
Gardin C; Dombret H
Curr Hematol Malig Rep; 2017 Feb; 12(1):1-10. PubMed ID: 28286907
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia.
Santini V; Lübbert M; Wierzbowska A; Ossenkoppele GJ
Adv Ther; 2022 Apr; 39(4):1474-1488. PubMed ID: 34786648
[TBL] [Abstract][Full Text] [Related]
17. The role of hypomethylating agents in the treatment of elderly patients with AML.
Al-Ali HK; Jaekel N; Niederwieser D
J Geriatr Oncol; 2014 Jan; 5(1):89-105. PubMed ID: 24484723
[TBL] [Abstract][Full Text] [Related]
18. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.
Boddu P; Kantarjian H; Garcia-Manero G; Ravandi F; Jabbour E; Borthakur G; Daver N; Pemmaraju N; Pierce S; Cortes J; Kadia TM
Leuk Lymphoma; 2018 Apr; 59(4):1012-1015. PubMed ID: 28838278
[No Abstract] [Full Text] [Related]
19. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.
Zeidan AM; Wang R; Wang X; Shallis RM; Podoltsev NA; Bewersdorf JP; Huntington SF; Neparidze N; Giri S; Gore SD; Davidoff AJ; Ma X
Blood Adv; 2020 May; 4(10):2192-2201. PubMed ID: 32433746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
